Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013. Lancet. 2015;386(10010): 2287–323.
DOI: https://doi.org/10.1016/S0140-6736(15)00128-2
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 Countries. Circulation. 2016;134(6):441–50.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.018912
Hird T, Zomer E, Owen A, Magliano D, Liew D, Ademi Z. Productivity burden of hypertension in Australia. Hypertension. 2019;73(4):777–84.
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.12606
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.
DOI: https://doi.org/10.1016/S0140-6736(15)01225-8
SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.
DOI: https://doi.org/10.1056/NEJMoa1511939
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.
DOI: https://doi.org/10.1161/01.HYP.0000107251.49515.c2
Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.111.068064
Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population-based cohort study. J Am Heart Assoc. 2017;6(6):e006056.
DOI: https://doi.org/10.1161/JAHA.117.006056
Katholi RE, Rocha-Singh KJ. The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance? Prog Cardiovasc Dis. 2009;52(3):243–8.
DOI: https://doi.org/10.1016/j.pcad.2009.09.003
Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11(1):3–20.
DOI: https://doi.org/10.1161/01.HYP.11.1.3
Schultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension. 2007;50(1):6–13.
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.106.076083
Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–82.
DOI: https://doi.org/10.1152/physrev.1991.71.3.659
Schiller AM, Haack KK, Pellegrino PR, Curry PL, Zucker IH. Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure. Am J Physiol Regul Integr Comp Physiol. 2013;305(8):R886–92.
DOI: https://doi.org/10.1152/ajpregu.00269.2013
Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–4.
DOI: https://doi.org/10.1001/jama.1953.03690160001001
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
DOI: https://doi.org/10.1016/S0140-6736(09)60566-3
Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7.
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.110.163014
Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9.
DOI: https://doi.org/10.1016/S0140-6736(13)62192-3
Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.
DOI: https://doi.org/10.1016/S0140-6736(10)62039-9
Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9.
DOI: https://doi.org/10.1093/eurheartj/ehu209
Kandzari DE, Bhatt DL, Sobotka PA, O'Neil WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35(9):528– 35.
DOI: https://doi.org/10.1002/clc.22008
Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27.
DOI: https://doi.org/10.1093/eurheartj/ehu441
Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, et al. The SPYRAL HTN global clinical trial program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFFMED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. 2016;171(1):82–91.
DOI: https://doi.org/10.1016/j.ahj.2015.08.021
Osborn JW, Banek CT. Catheter-based renal nerve ablation as a novel hypertension therapy: lost, and then found, in translation. Hypertension. 2018;71(3):383–8.
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.08928
Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–51.
DOI: https://doi.org/10.1016/S0140-6736(20)30554-7
Mahfoud F, Böhm M, Azizi M, Pathak, Zaleski ID, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27.
DOI: https://doi.org/10.1093/eurheartj/ehv192